{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25261308",
  "DateCompleted": {
    "Year": "2015",
    "Month": "06",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2014",
    "Month": "09",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/978-1-4939-1571-2_7"
    ],
    "Journal": {
      "ISSN": "1940-6029",
      "JournalIssue": {
        "Volume": "1221",
        "PubDate": {
          "Year": "2015"
        }
      },
      "Title": "Methods in molecular biology (Clifton, N.J.)",
      "ISOAbbreviation": "Methods Mol Biol"
    },
    "ArticleTitle": "Infectivity assays of human rhinovirus-A and -B serotypes.",
    "Pagination": {
      "StartPage": "71",
      "EndPage": "81",
      "MedlinePgn": "71-81"
    },
    "Abstract": {
      "AbstractText": [
        "Infectivity is a fundamental property of viral pathogens such as human rhinoviruses (HRVs). This chapter describes two methods for measuring the infectivity of HRV-A and -B serotypes: end point dilution (TCID50) assay and plaque assay. End point dilution assay is a quantal, not quantitative, assay that determines the dilution of the sample at which 50 % of the aliquots have infectious virus. It can be used for all the HRV-A and -B serotypes and related clinical isolates that grow in cell culture and induce cytopathic effect (CPE), degenerative changes in cells that are visible under a microscope. Plaque assay is a quantitative assay that determines the number of infectious units of a virus in a sample. After an infectious unit of virus infects one cell, the infected cell produces progeny viruses that then infect and kill a circle of adjacent cells. This circle of dead cells detaches from the dish and thus leaves a clear hole in a cell monolayer. Plaque assay works only for HeLa-adapted HRV-A and -B serotypes that can make visible plaques on the cell monolayer. Currently the end point dilution assay and plaque assay have not been developed for the newly discovered HRV-C."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biological Mimetics Inc., 124 Byte Drive, Frederick, MD, 21702, USA, wlee5hkg@gmail.com."
          }
        ],
        "LastName": "Lee",
        "ForeName": "Wai-Ming",
        "Initials": "WM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Chen",
        "ForeName": "Yin",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wang",
        "ForeName": "Wensheng",
        "Initials": "W"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mosser",
        "ForeName": "Anne",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Methods Mol Biol",
    "NlmUniqueID": "9214969",
    "ISSNLinking": "1064-3745"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Cryopreservation"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "HeLa Cells"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "growth & development",
        "pathogenicity"
      ],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Serogroup"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Viral Plaque Assay"
    }
  ]
}